BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-949@pharmaconomics
DTSTAMP:20260707T025250Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:CCCC Phase 3 — cemsidomide (estimated date)
DESCRIPTION:Phase 3 trial results for cemsidomide in Multiple Myeloma are due ~ Jan 1\, 2028. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1662579/000162828026024336/aprilcorporatedeck_final.htm\n\nTrack it: https://pharmaconomics.com/e/949
URL:https://pharmaconomics.com/e/949
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:CCCC catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR